J&J Oncology Head Confident About Fast-Tracked Daratumumab's Chances
This article was originally published in Scrip
Johnson & Johnson says it is increasingly confident its anti-CD38 monoclonal antibody daratumumab will get final approval in both the US and Europe after being fast-tracked by regulators in both regions for treating multiple myeloma, an incurable blood cancer.
You may also be interested in...
EXACT-Tx will use funds from a NOK155m private placing to harness ultrasound in precision therapeutic targeting across a variety of indications and product classes.
The Nordic region’s vibrant life sciences ecosystem will be the chief focus for newly created Eir Ventures, a strategic partnership and investment company.
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.